Cargando…
TGF-β1 of no avail as prognostic marker in lyme disease
Background. Within the present in vivo study using the wild type mouse strains C3H/HeN and FVB/N it was intended to (1) measure TGF-β1 expression in the course of lyme disease, (2) examine the potential correlation of TGF-β1 expression with the clinical outcome of a Borrelia infection (with a focus...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045338/ https://www.ncbi.nlm.nih.gov/pubmed/24918028 http://dx.doi.org/10.7717/peerj.398 |
_version_ | 1782319300826103808 |
---|---|
author | Schumann, Julia |
author_facet | Schumann, Julia |
author_sort | Schumann, Julia |
collection | PubMed |
description | Background. Within the present in vivo study using the wild type mouse strains C3H/HeN and FVB/N it was intended to (1) measure TGF-β1 expression in the course of lyme disease, (2) examine the potential correlation of TGF-β1 expression with the clinical outcome of a Borrelia infection (with a focus on lyme arthritis), (3) develop a diagnostic tool based on the endogenous factor TGF-β1 to predict the progressivity of lyme disease. Findings. In the course of lyme disease there was an increase in the serum content of active TGF-β1, which became significant 56 days post infection (p < 0.001). The serum concentration of total TGF-β1 in the course of infection initially decreased then rebounded and subsequently dropped again. Despite considerable individual variations in active TGF-β1 serum concentrations there were no identifiable dissimilarities in the clinical appearance of the mice. Likewise, no correlation could be seen between the serum content of active TGF-β1 and the severity of lyme arthritis of tibiotarsal joints of infected mice. Conclusions. The present study clearly shows that TGF-β1 is of no avail as prognostic marker in lyme disease. Hence, the search for an endogenous predictive factor, which can be determined in an easy and reliable manner, remains open. |
format | Online Article Text |
id | pubmed-4045338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-40453382014-06-10 TGF-β1 of no avail as prognostic marker in lyme disease Schumann, Julia PeerJ Immunology Background. Within the present in vivo study using the wild type mouse strains C3H/HeN and FVB/N it was intended to (1) measure TGF-β1 expression in the course of lyme disease, (2) examine the potential correlation of TGF-β1 expression with the clinical outcome of a Borrelia infection (with a focus on lyme arthritis), (3) develop a diagnostic tool based on the endogenous factor TGF-β1 to predict the progressivity of lyme disease. Findings. In the course of lyme disease there was an increase in the serum content of active TGF-β1, which became significant 56 days post infection (p < 0.001). The serum concentration of total TGF-β1 in the course of infection initially decreased then rebounded and subsequently dropped again. Despite considerable individual variations in active TGF-β1 serum concentrations there were no identifiable dissimilarities in the clinical appearance of the mice. Likewise, no correlation could be seen between the serum content of active TGF-β1 and the severity of lyme arthritis of tibiotarsal joints of infected mice. Conclusions. The present study clearly shows that TGF-β1 is of no avail as prognostic marker in lyme disease. Hence, the search for an endogenous predictive factor, which can be determined in an easy and reliable manner, remains open. PeerJ Inc. 2014-05-27 /pmc/articles/PMC4045338/ /pubmed/24918028 http://dx.doi.org/10.7717/peerj.398 Text en © 2014 Schumann http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Immunology Schumann, Julia TGF-β1 of no avail as prognostic marker in lyme disease |
title | TGF-β1 of no avail as prognostic marker in lyme disease |
title_full | TGF-β1 of no avail as prognostic marker in lyme disease |
title_fullStr | TGF-β1 of no avail as prognostic marker in lyme disease |
title_full_unstemmed | TGF-β1 of no avail as prognostic marker in lyme disease |
title_short | TGF-β1 of no avail as prognostic marker in lyme disease |
title_sort | tgf-β1 of no avail as prognostic marker in lyme disease |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045338/ https://www.ncbi.nlm.nih.gov/pubmed/24918028 http://dx.doi.org/10.7717/peerj.398 |
work_keys_str_mv | AT schumannjulia tgfb1ofnoavailasprognosticmarkerinlymedisease |